Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 9 | 2017 | 530 | 1.550 |
Why?
|
| Diagnostic Imaging | 9 | 2015 | 462 | 1.160 |
Why?
|
| Prostate | 7 | 2025 | 413 | 1.070 |
Why?
|
| Prostatic Neoplasms | 11 | 2025 | 1769 | 0.950 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2015 | 2686 | 0.910 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2025 | 3480 | 0.860 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2017 | 342 | 0.840 |
Why?
|
| Embolization, Therapeutic | 4 | 2021 | 254 | 0.820 |
Why?
|
| Prostatic Hyperplasia | 2 | 2019 | 91 | 0.700 |
Why?
|
| Radiology | 5 | 2017 | 205 | 0.630 |
Why?
|
| Testicular Neoplasms | 2 | 2023 | 120 | 0.610 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 1395 | 0.570 |
Why?
|
| Ultrasonography | 8 | 2023 | 719 | 0.490 |
Why?
|
| Epididymitis | 1 | 2014 | 5 | 0.470 |
Why?
|
| Spermatic Cord | 1 | 2014 | 6 | 0.470 |
Why?
|
| Practice Guidelines as Topic | 6 | 2015 | 1077 | 0.460 |
Why?
|
| Radiographic Image Enhancement | 2 | 2014 | 466 | 0.450 |
Why?
|
| Contrast Media | 7 | 2015 | 1079 | 0.450 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2011 | 81 | 0.440 |
Why?
|
| Scrotum | 4 | 2023 | 18 | 0.430 |
Why?
|
| Hemangioma | 2 | 2011 | 65 | 0.420 |
Why?
|
| Chyle | 1 | 2012 | 5 | 0.390 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2012 | 9 | 0.390 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 2012 | 6 | 0.390 |
Why?
|
| Surgical Sponges | 1 | 2011 | 3 | 0.390 |
Why?
|
| Tuberculosis, Endocrine | 1 | 2011 | 1 | 0.390 |
Why?
|
| Adrenal Gland Diseases | 1 | 2011 | 14 | 0.390 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2011 | 12 | 0.380 |
Why?
|
| Orchitis | 1 | 2011 | 10 | 0.380 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2011 | 11 | 0.380 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 186 | 0.380 |
Why?
|
| Granuloma | 1 | 2011 | 64 | 0.370 |
Why?
|
| Medical Oncology | 2 | 2013 | 392 | 0.360 |
Why?
|
| Ileum | 1 | 2011 | 168 | 0.360 |
Why?
|
| Foreign Bodies | 1 | 2011 | 64 | 0.360 |
Why?
|
| Kidney | 3 | 2015 | 1159 | 0.360 |
Why?
|
| Urinary Bladder | 1 | 2012 | 251 | 0.340 |
Why?
|
| Middle Aged | 19 | 2025 | 26991 | 0.330 |
Why?
|
| Humans | 45 | 2025 | 92134 | 0.330 |
Why?
|
| Diagnosis, Differential | 11 | 2023 | 1600 | 0.320 |
Why?
|
| Carcinoma | 1 | 2011 | 437 | 0.290 |
Why?
|
| Male | 28 | 2025 | 43796 | 0.290 |
Why?
|
| Positron-Emission Tomography | 2 | 2025 | 340 | 0.290 |
Why?
|
| Nephrectomy | 4 | 2015 | 293 | 0.290 |
Why?
|
| Image-Guided Biopsy | 4 | 2025 | 80 | 0.280 |
Why?
|
| Testis | 2 | 2011 | 152 | 0.280 |
Why?
|
| Angiomyolipoma | 2 | 2017 | 17 | 0.270 |
Why?
|
| Prostate-Specific Antigen | 4 | 2025 | 343 | 0.260 |
Why?
|
| Testicular Diseases | 2 | 2018 | 9 | 0.250 |
Why?
|
| Kidney Diseases, Cystic | 2 | 2015 | 22 | 0.240 |
Why?
|
| Urea | 1 | 2025 | 60 | 0.240 |
Why?
|
| Kidney Transplantation | 1 | 2011 | 861 | 0.230 |
Why?
|
| Neoplasm Staging | 3 | 2025 | 2035 | 0.220 |
Why?
|
| Prostatectomy | 2 | 2025 | 478 | 0.220 |
Why?
|
| Lysine | 1 | 2025 | 182 | 0.210 |
Why?
|
| Aged | 12 | 2025 | 19913 | 0.210 |
Why?
|
| Clinical Decision-Making | 1 | 2025 | 287 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 6911 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 2555 | 0.190 |
Why?
|
| Prospective Studies | 5 | 2025 | 4457 | 0.190 |
Why?
|
| Arteries | 2 | 2019 | 178 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 3766 | 0.180 |
Why?
|
| Brachytherapy | 1 | 2021 | 120 | 0.170 |
Why?
|
| Female | 13 | 2015 | 47767 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 100 | 0.170 |
Why?
|
| Radiology Information Systems | 1 | 2020 | 78 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 2394 | 0.160 |
Why?
|
| Endosonography | 1 | 2019 | 100 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2012 | 372 | 0.140 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2017 | 34 | 0.140 |
Why?
|
| Physician Assistants | 1 | 2017 | 21 | 0.140 |
Why?
|
| Radiologists | 1 | 2017 | 51 | 0.130 |
Why?
|
| Biopsy | 4 | 2025 | 1197 | 0.130 |
Why?
|
| Retrospective Studies | 7 | 2025 | 9619 | 0.130 |
Why?
|
| Radiography | 3 | 2012 | 806 | 0.120 |
Why?
|
| Physician's Role | 1 | 2017 | 178 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2793 | 0.120 |
Why?
|
| Predictive Value of Tests | 4 | 2025 | 1762 | 0.120 |
Why?
|
| Flank Pain | 1 | 2012 | 5 | 0.100 |
Why?
|
| Observer Variation | 1 | 2014 | 614 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 408 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 389 | 0.100 |
Why?
|
| Urinary Calculi | 1 | 2012 | 46 | 0.100 |
Why?
|
| Curriculum | 1 | 2017 | 577 | 0.100 |
Why?
|
| Mass Screening | 2 | 2017 | 667 | 0.100 |
Why?
|
| Cystitis | 1 | 2012 | 14 | 0.100 |
Why?
|
| Acute Pain | 1 | 2012 | 12 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2019 | 2972 | 0.100 |
Why?
|
| United States | 6 | 2017 | 7312 | 0.090 |
Why?
|
| Pelvis | 1 | 2012 | 96 | 0.090 |
Why?
|
| Urinary Diversion | 1 | 2011 | 43 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 78 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2012 | 297 | 0.090 |
Why?
|
| Paraganglioma | 1 | 2011 | 15 | 0.090 |
Why?
|
| Lymphatic Vessels | 1 | 2012 | 69 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2011 | 164 | 0.090 |
Why?
|
| Ureteral Obstruction | 1 | 2012 | 70 | 0.090 |
Why?
|
| Rituximab | 1 | 2011 | 122 | 0.090 |
Why?
|
| Pelvic Pain | 1 | 2012 | 85 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 232 | 0.090 |
Why?
|
| Young Adult | 2 | 2014 | 6597 | 0.090 |
Why?
|
| Prostatic Diseases | 1 | 2010 | 3 | 0.090 |
Why?
|
| Lipids | 1 | 2012 | 278 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 570 | 0.090 |
Why?
|
| Urination Disorders | 1 | 2010 | 54 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 323 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2025 | 2015 | 0.080 |
Why?
|
| Lipoma | 1 | 2010 | 27 | 0.080 |
Why?
|
| Kidney Calices | 1 | 2008 | 5 | 0.080 |
Why?
|
| Kidney Diseases | 2 | 2008 | 324 | 0.080 |
Why?
|
| Adult | 8 | 2017 | 27478 | 0.080 |
Why?
|
| Lithium | 1 | 2008 | 63 | 0.080 |
Why?
|
| Patient Selection | 1 | 2012 | 689 | 0.080 |
Why?
|
| Kidney Medulla | 1 | 2008 | 80 | 0.070 |
Why?
|
| Liver Neoplasms | 2 | 2005 | 766 | 0.070 |
Why?
|
| Cysts | 1 | 2008 | 103 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2010 | 294 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2019 | 8689 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2005 | 256 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2020 | 598 | 0.050 |
Why?
|
| ROC Curve | 2 | 2019 | 786 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2002 | 41 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2025 | 894 | 0.050 |
Why?
|
| Adolescent | 1 | 2014 | 9488 | 0.050 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 46 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 2366 | 0.040 |
Why?
|
| Dogs | 1 | 2021 | 704 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2003 | 409 | 0.040 |
Why?
|
| Pain | 1 | 2002 | 407 | 0.040 |
Why?
|
| Hemospermia | 1 | 2018 | 2 | 0.040 |
Why?
|
| Dysuria | 1 | 2018 | 8 | 0.040 |
Why?
|
| Urinary Retention | 1 | 2018 | 43 | 0.040 |
Why?
|
| Rectum | 1 | 2019 | 149 | 0.040 |
Why?
|
| Hematuria | 1 | 2018 | 50 | 0.040 |
Why?
|
| Urodynamics | 1 | 2018 | 123 | 0.040 |
Why?
|
| Angiography | 1 | 2018 | 203 | 0.040 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2018 | 64 | 0.040 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2018 | 74 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 1266 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1767 | 0.030 |
Why?
|
| False Positive Reactions | 2 | 2005 | 222 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 208 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 106 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1504 | 0.030 |
Why?
|
| Catheter Ablation | 1 | 2015 | 249 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2012 | 38 | 0.020 |
Why?
|
| Decision Making | 1 | 2017 | 679 | 0.020 |
Why?
|
| Cognition | 1 | 2016 | 594 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 1740 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 304 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 107 | 0.020 |
Why?
|
| Stents | 1 | 2012 | 415 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 899 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 172 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 695 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 170 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 3860 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 144 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 28052 | 0.010 |
Why?
|